<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490683</url>
  </required_header>
  <id_info>
    <org_study_id>5150056</org_study_id>
    <nct_id>NCT02490683</nct_id>
  </id_info>
  <brief_title>Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.</brief_title>
  <official_title>The Effect of Soy-based Dietary Supplements on Cardiometabolic Risk Factors in Individuals at High Risk for Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effect of both Luna Rich X© and Reliv Now© against placebo pills or&#xD;
      powder (control) on blood lipids. It will also explore the potential effects of these dietary&#xD;
      supplements on inflammation markers and other biological and anthropometric measures. The&#xD;
      study intervention will be 30 weeks in length. Twenty four subjects with 2 or more&#xD;
      cardiometabolic risk factors will be randomized to participate in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective To test the effects of Luna Rich X©, and Reliv Now© on serum lipids and&#xD;
      selected inflammatory and oxidative parameters.&#xD;
&#xD;
      Secondary Objective To explore the potential effects of Luna Rich X© and Reliv Now© on body&#xD;
      weight and adiposity.&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
        1. Eight-week supplementation of formulated lunasin-enriched soy concentrate (Luna Rich X©)&#xD;
           in adults at risk for cardiovascular disease will improve their serum lipid profile and&#xD;
           reduce inflammatory parameters.&#xD;
&#xD;
        2. Eight-week supplementation of a formulated soy-based powder (Reliv Now) plus Luna Rich X&#xD;
           in adults at risk for cardiovascular disease will improve their serum lipid profile and&#xD;
           reduce inflammatory parameters.&#xD;
&#xD;
      Study Protocol&#xD;
&#xD;
      Recruitment of Subjects Subjects will be recruited from out-patient clinics in or near Loma&#xD;
      Linda University. In collaboration with the medical personnel of the Family and Internal&#xD;
      Medicine clinics of the Loma Linda University and Beaver Medical Group, interested&#xD;
      clients/patients will be referred to the study. Potential subjects will be informed about the&#xD;
      study by the physician, nurse or other clinic personnel and will be given a flyer.&#xD;
      Individuals will make their own decision whether or not to participate in the study. The&#xD;
      clients/patients who will be interested in participating in the study will contact the&#xD;
      investigators via the provided phone numbers. A dedicated telephone line and webpage will&#xD;
      provide both additional information to interested individuals and a means to screen out&#xD;
      subjects by the study personnel. Potential subjects will first be screened by study&#xD;
      personnel, and then directed to a clinical laboratory at Loma Linda University for&#xD;
      determination of biochemical parameters on which the eligibility for the study will be&#xD;
      determined.&#xD;
&#xD;
      Dietary Interventions&#xD;
&#xD;
        -  Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate&#xD;
&#xD;
        -  Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or&#xD;
           a beverage they commonly drink.&#xD;
&#xD;
        -  Control: Placebo pills containing starch (provided by Reliv International, Inc.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Lipid profile</measure>
    <time_frame>baseline- 30 weeks</time_frame>
    <description>Serum Low density cholesterol, high density cholesterol, apo Lipoprotein A and B, apo E allele genetic typing and triglycerides will be measured from the by performing lab tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory and oxidative parameters</measure>
    <time_frame>baseline- 30 weeks</time_frame>
    <description>hs-CRP (highly sensitive C-reactive protein), TNF-alpha (tissue necrosis factor alpha), IL-6 (Interleukin 6), ox-LDL (oxidized low density lipoprotein), TBARS (thiobarbituric acid reactive substances) lipid peroxides, 8-OHdG (8-hydroxy-2-deoxyguanosine) will be measured via lab tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormones</measure>
    <time_frame>baseline- 30 weeks</time_frame>
    <description>: adiponectin, leptin, insulin, C-peptide (C-peptide of insulin); and fasting glucose and hemoglobin A1c. will be measured via lab tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>baseline -30 weeks</time_frame>
    <description>, blood samples will be taken for testing levels of lunasin and/or its metabolites as biological marker(s) of the treatment compliance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <condition>Cardiovascular Risk Factors</condition>
  <arm_group>
    <arm_group_label>Luna Rich X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reliv Now</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills containing starch (provided by Reliv International, Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Luna Rich X</intervention_name>
    <arm_group_label>Luna Rich X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Reliv Now</intervention_name>
    <arm_group_label>Reliv Now</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Men and women 35-75 years of age, at high risk for cardiovascular disease, i.e. with 2&#xD;
        or more risk factors:&#xD;
&#xD;
          -  Present tobacco smoker&#xD;
&#xD;
          -  Arterial hypertension (BP ≥140/90 mm Hg or treatment)&#xD;
&#xD;
          -  LDL-cholesterol ≥130 mg/dl&#xD;
&#xD;
          -  HDL-cholesterol ≤ 40 mg/dl&#xD;
&#xD;
          -  Triglycerides ≥150 mg/dl&#xD;
&#xD;
          -  Fasting blood glucose ≥110 mg/dl&#xD;
&#xD;
          -  Overweight or obesity (BMI ≥ 25 kg/m2)&#xD;
&#xD;
          -  Family history of premature heart disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled renal/hepatic/endocrine disease&#xD;
&#xD;
          2. Abnormal blood chemistry profile&#xD;
&#xD;
          3. Familial hypercholesterolemia or other genetic dyslipidaemia&#xD;
&#xD;
          4. Intake of lipid-lowering drugs and dietary products including plant sterols/stanols&#xD;
&#xD;
          5. High Framingham risk or medical condition in which statin therapy is considered&#xD;
             necessary by a treating physician&#xD;
&#xD;
          6. Hypersensitive or allergic to soy&#xD;
&#xD;
          7. Alcohol or drug addiction/abuse&#xD;
&#xD;
          8. Diabetics&#xD;
&#xD;
          9. Impossibility or lack of interest to follow the dietary intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Sabate, DrPH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University School of Public Health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Joan Sabate,DrPH, MD</investigator_full_name>
    <investigator_title>DrPH, MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

